CPHA Canvax

KEY POINTS

  • Immunization with a safe and effective vaccine could hasten control of the coronavirus disease 2019 (COVID-19) pandemic and minimize morbidity, death and societal disruption that have resulted from it.
  • Canada’s National Advisory Committee on Immunization (NACI) has developed preliminary recommendations for the efficient, effective and equitable allocation of safe, efficacious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine(s) in the context of staggered arrival of vaccines.
  • Key populations for early vaccination include those at high risk of severe illness and death from COVID-19; those most likely to transmit COVID-19 to those at high risk of severe illness and death from COVID-19 and workers essential to maintaining the COVID-19 response; those contributing to the maintenance of other essential services for the functioning of society; and those whose living or working conditions put them at elevated risk of infection and where infection could have disproportionate consequences, including Indigenous communities.
  • Sequencing of key populations will be determined once more information about SARS-CoV-2 vaccine(s) becomes available; integration of equity, feasibility and acceptability considerations across all populations is critical for decisions regarding a COVID-19 immunization program.
  • Transparent, clear communication about SARS-CoV-2 vaccines and vaccine allocation decisions to the public and health care providers is important to establish and maintain trust and confidence, and improve access to vaccines.
Rating See Comments Ratings

Category:

Program Planning and Delivery,Vaccine Management,Allocation and Distribution,Policy,Immunization Policies,Evaluations,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Program Planning and Delivery
Vaccine Management
Allocation and Distribution
Policy
Immunization Policies
Evaluations
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.